SG11201809677XA - Cd200 mutant and its uses - Google Patents
Cd200 mutant and its usesInfo
- Publication number
- SG11201809677XA SG11201809677XA SG11201809677XA SG11201809677XA SG11201809677XA SG 11201809677X A SG11201809677X A SG 11201809677XA SG 11201809677X A SG11201809677X A SG 11201809677XA SG 11201809677X A SG11201809677X A SG 11201809677XA SG 11201809677X A SG11201809677X A SG 11201809677XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lane
- protein
- blenheim
- freeland
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111101011111111111 0111011111011111111011111101111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/194941 Al 16 November 2017 (16.11.2017) WIPO I PCT (51) International Patent Classification: (74) Agent: GIBSON, Mark et al.; Sagittarius IP, Three Globe- C07K 14/705 (2006.01) A61K 38/17(2006.01) side, Fieldhouse Lane, Marlow Buckinghamshire SL7 1HZ C12N 15/62 (2006.01) (GB). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/GB2017/051303 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 10 May 2017 (10.05.2017) CA, DZ, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (26) Publication Language: English KW, MK, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 1608197.8 10 May 2016 (10.05.2016) GB SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: DUCENTIS BIOTHERAPEUTICS LTD. [GB/GB]; 9 Blenheim Lane, Freeland, Witney Oxfordshire (84) Designated States (unless otherwise indicated, for every OX29 8AW (GB). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (72) Inventors: HUXLEY, Philip; c/o Ducentis Biotherapeu-UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, tics Ltd., 9 Blenheim Lane, Freeland, Witney Oxfordshire TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — OX29 8AW (GB). SHERIDAN, Joseph; c/o Ducentis Bio-EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, therapeutics Ltd., 9 Blenheim Lane, Freeland, Witney Ox- MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = fordshire OX29 8AW (GB). HEAL, Jonathan; c/o Ducen- TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, tis Biotherapeutics Ltd., 9 Blenheim Lane, Freeland, Wit-KM, ney Oxfordshire OX29 8AW (GB). ML, MR, NE, SN, TD, TG). = (54) Title: CD200 MUTANT AND ITS USES FIGURE 6 Dose response results comparing the inhibition of PMA stimulated oxidative burst in isolated human neutrophils by wild-type CD200-Fc and K130Y = = , \" voy, * = = — 0 = = s 0 f3 a = = X*j 0 a. a A ril 0 5 E P p , • i = CO; • Il Il 7r CI ' 7r CI ' (57) : The invention relates generally to mutant CD200 proteins which bind with greater affinity to the CD200 receptor than ---- wild IN -type CD200, in particular the invention relates to a mutated CD200 protein comprising a mutation at amino acid residue position ,1 130 and/or 131. This invention also relates to a fusion protein comprising the protein as defined herein fused to a non-CD200 protein 0 encoding portion via an optional linker portion, a pharmaceutical composition comprising ei the protein as defined herein and uses thereof. O [Continued on next page] WO 2017/194941 Al MIDEDIMOMOIDEIROIDEMOMOHEIBIOSHIMOVOIMIE Published: — with international search report (Art. 21(3)) — with amended claims and statement (Art. 19(1)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1608197.8A GB201608197D0 (en) | 2016-05-10 | 2016-05-10 | Novel proteins |
PCT/GB2017/051303 WO2017194941A1 (en) | 2016-05-10 | 2017-05-10 | Cd200 mutant and its uses |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809677XA true SG11201809677XA (en) | 2018-11-29 |
Family
ID=56297468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809677XA SG11201809677XA (en) | 2016-05-10 | 2017-05-10 | Cd200 mutant and its uses |
Country Status (15)
Country | Link |
---|---|
US (1) | US11203628B2 (en) |
EP (1) | EP3455247A1 (en) |
JP (1) | JP6997767B2 (en) |
KR (2) | KR102498901B1 (en) |
CN (1) | CN109219614B (en) |
AU (1) | AU2017264825B2 (en) |
BR (1) | BR112018073280A2 (en) |
CA (1) | CA3023601A1 (en) |
EA (1) | EA201892554A1 (en) |
GB (1) | GB201608197D0 (en) |
IL (1) | IL262846B2 (en) |
MX (1) | MX2018013778A (en) |
SG (1) | SG11201809677XA (en) |
WO (1) | WO2017194941A1 (en) |
ZA (1) | ZA201807079B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201608197D0 (en) | 2016-05-10 | 2016-06-22 | Ducentis Biotherapeutics Ltd | Novel proteins |
KR102186780B1 (en) | 2019-02-18 | 2020-12-04 | 박주현 | A manned drone that separates the flight part from the occupant and combines it with an axis |
CN110859951A (en) * | 2019-09-23 | 2020-03-06 | 中国药科大学 | Application of CD200 protein and CD200 fusion protein in preparation of psoriasis treatment drugs |
GB202115803D0 (en) * | 2021-11-03 | 2021-12-15 | Ducentis Biotherapeutics Ltd | Novel proteins |
WO2023214388A1 (en) * | 2022-05-06 | 2023-11-09 | Ducentis Biotherapeutics Limited | Novel cd200 fusion proteins |
WO2023214387A1 (en) * | 2022-05-06 | 2023-11-09 | Ducentis Biotherapeutics Limited | Novel cd200 fusion proteins |
GB2626300A (en) * | 2022-12-08 | 2024-07-24 | Ducentis Biotherapeutics Ltd | Mutated CD200 proteins and methods of use therof |
GB202303291D0 (en) | 2023-03-07 | 2023-04-19 | Secr Defence | Medicament and medicament combination for use in the treatment of infectious disease |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE319825T1 (en) * | 1997-11-07 | 2006-03-15 | Trillium Therapeutics Inc | METHODS AND COMPOSITIONS FOR IMMUNOMODULATION |
US7223729B2 (en) * | 1997-11-07 | 2007-05-29 | Trillium Therapeutics Inc. | Methods of treating allergy by administering a CD200 protein |
CA2369454A1 (en) | 1999-04-13 | 2000-10-19 | Schering Corporation | Uses of mammalian ox2 protein and related reagents |
CA2402293A1 (en) * | 2000-03-07 | 2001-09-13 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
ATE406385T1 (en) | 2000-11-22 | 2008-09-15 | Trillium Therapeutics Inc | SHORTENED CD200 |
WO2007024715A2 (en) * | 2005-08-19 | 2007-03-01 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
JP2010515751A (en) | 2007-01-11 | 2010-05-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | CD200 and its receptor CD200R regulate bone mass through osteoclast differentiation |
US8753639B2 (en) * | 2009-03-31 | 2014-06-17 | University Of Washington Through Its Center For Commercialization | Compositions and methods for modulating the activity of complement regulatory proteins on target cells |
CA2786692A1 (en) * | 2010-01-11 | 2011-07-14 | Alexion Pharmaceuticals, Inc. | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
GB201608197D0 (en) | 2016-05-10 | 2016-06-22 | Ducentis Biotherapeutics Ltd | Novel proteins |
-
2016
- 2016-05-10 GB GBGB1608197.8A patent/GB201608197D0/en not_active Ceased
-
2017
- 2017-05-10 CA CA3023601A patent/CA3023601A1/en active Pending
- 2017-05-10 KR KR1020187035514A patent/KR102498901B1/en active IP Right Grant
- 2017-05-10 AU AU2017264825A patent/AU2017264825B2/en active Active
- 2017-05-10 WO PCT/GB2017/051303 patent/WO2017194941A1/en unknown
- 2017-05-10 MX MX2018013778A patent/MX2018013778A/en unknown
- 2017-05-10 BR BR112018073280-0A patent/BR112018073280A2/en unknown
- 2017-05-10 JP JP2019511816A patent/JP6997767B2/en active Active
- 2017-05-10 US US16/300,382 patent/US11203628B2/en active Active
- 2017-05-10 KR KR1020237004504A patent/KR102689460B1/en active IP Right Grant
- 2017-05-10 EP EP17724607.1A patent/EP3455247A1/en active Pending
- 2017-05-10 SG SG11201809677XA patent/SG11201809677XA/en unknown
- 2017-05-10 CN CN201780028505.0A patent/CN109219614B/en active Active
- 2017-05-10 EA EA201892554A patent/EA201892554A1/en unknown
-
2018
- 2018-10-24 ZA ZA2018/07079A patent/ZA201807079B/en unknown
- 2018-11-07 IL IL262846A patent/IL262846B2/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN109219614A (en) | 2019-01-15 |
EA201892554A1 (en) | 2019-04-30 |
CN109219614B (en) | 2022-05-24 |
IL262846B (en) | 2022-10-01 |
JP2019518788A (en) | 2019-07-04 |
US20190367580A1 (en) | 2019-12-05 |
KR20230025937A (en) | 2023-02-23 |
EP3455247A1 (en) | 2019-03-20 |
ZA201807079B (en) | 2019-07-31 |
AU2017264825B2 (en) | 2021-04-08 |
IL262846A (en) | 2018-12-31 |
AU2017264825A1 (en) | 2018-11-15 |
KR102689460B1 (en) | 2024-07-26 |
CA3023601A1 (en) | 2017-11-16 |
WO2017194941A1 (en) | 2017-11-16 |
BR112018073280A2 (en) | 2019-03-19 |
KR102498901B1 (en) | 2023-02-10 |
IL262846B2 (en) | 2023-02-01 |
US11203628B2 (en) | 2021-12-21 |
JP6997767B2 (en) | 2022-03-04 |
MX2018013778A (en) | 2019-08-01 |
KR20190003761A (en) | 2019-01-09 |
GB201608197D0 (en) | 2016-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809677XA (en) | Cd200 mutant and its uses | |
SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
SG11201903674YA (en) | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201809041TA (en) | Compositions and methods for selective protein expression | |
SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201908650PA (en) | Optimized antibody compositions for treatment of ocular disorders | |
SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
SG11201907422RA (en) | Anti-tau antibodies and methods of use thereof | |
SG11201804294WA (en) | Tank-binding kinase inhibitor compounds | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
SG11201803642WA (en) | Bacteria-based protein delivery | |
SG11201808830YA (en) | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201903348UA (en) | Therapeutic compounds and methods of use thereof | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201806852PA (en) | Protein purification | |
SG11201804589TA (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
SG11201909793YA (en) | AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds |